Tolterodine for the treatment of urge urinary incontinence

Expert Opin Pharmacother. 2013 Oct;14(14):1987-91. doi: 10.1517/14656566.2013.823158. Epub 2013 Jul 26.

Abstract

Introduction: Overactive bladder (OAB) and its resultant urge urinary incontinence (UUI) are significant problems that medically, psychologically and financially affect people. The constellation of symptoms comprising OAB affects ∼ 16% of the adult population and its prevalence increases with aging. The typical class of medications used to treat OAB is antimuscarinics.

Areas covered: OAB medications, with a focus on tolterodine for the treatment of UUI are reviewed. A thorough review of English language literature using EMBASE/Medline and PubMed has been performed.

Expert opinion: Tolterodine provides a reasonable starting point when treating patients with OAB and UUI. Efficacy and tolerability are generally comparable between tolterodine and other newer antimuscarinics. Tolterodine is a good option as part of the algorithm in the treatment of OAB and UUI.

Publication types

  • Review

MeSH terms

  • Benzhydryl Compounds / pharmacology
  • Benzhydryl Compounds / therapeutic use*
  • Cresols / pharmacology
  • Cresols / therapeutic use*
  • Humans
  • Muscarinic Antagonists / pharmacology
  • Muscarinic Antagonists / therapeutic use*
  • Phenylpropanolamine / pharmacology
  • Phenylpropanolamine / therapeutic use*
  • Tolterodine Tartrate
  • Treatment Outcome
  • Urinary Bladder, Overactive / drug therapy*
  • Urinary Incontinence, Urge / drug therapy*
  • Urological Agents / pharmacology
  • Urological Agents / therapeutic use*

Substances

  • Benzhydryl Compounds
  • Cresols
  • Muscarinic Antagonists
  • Urological Agents
  • Phenylpropanolamine
  • Tolterodine Tartrate